LUCA Biologics

📍 Cambridge, United States🗓 Founded 2019👥 4 employees💰 Last funded Aug 2019
Biotechnology Research🌐 luca.bio
Website LinkedIn
LUCA Biologics is a biotechnology company developing a new class of living medicines targeting the vaginal microbiome to impact reproductive and urogenital health. Emerging from the lab of Dr. Jacques Ravel, Primary Investigator on the vaginal microbiome division of the NIHs Human Microbiome Project, our platform takes a metagenomic and metatranscriptomic approach to the identification, screening and validation of strains with therapeutic potential. Our pipeline includes therapeutics for urinary tract infection (UTI), preterm birth (PTB), bacterial vaginosis (BV), and infertility. LUCA Biologics is a Seed Health foundry company.
3
Total investors
3
Early stage
0
Mid stage
0
Late stage
2019
Founded

Investors

3 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
3
Frequently asked questions
Who invested in LUCA Biologics?
LUCA Biologics has 3 investors on record on gritt.io, including 3 early-stage backers.
When did LUCA Biologics last raise funding?
The most recent investment in LUCA Biologics recorded on gritt.io was in August 2019.
When was LUCA Biologics founded?
LUCA Biologics was founded in 2019.
What industry is LUCA Biologics in?
LUCA Biologics operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is LUCA Biologics based?
LUCA Biologics is headquartered in Cambridge, United States.